Sanofi announced the launch of Oxaliplatin Injection, the generic version of its Eloxatin, through the company’s generic division Winthrop US.
Oxaliplatin, an alkylating agent, is indicated for adjuvant treatment for stage III colon cancer in patients who have undergone complete resection of the primary tumor (in combination with infusional 5-FU/LV), and for treatment of advanced colorectal cancer (in combination with infusional 5-FU/LV).
Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription.
Oxaliplatin Injection is available in 50mg and 100mg single-use vials.
For more information call (800) 981-2491 or visit WinthropUS.com.
This article originally appeared on MPR